Nolatrexed

Summary

Nolatrexed (CHEMBL320775) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 284.34 Da · C14H12N4OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL320775
Name	Nolatrexed
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135400184
Molecular formula	C14H12N4OS
Molecular weight	284.34
InChIKey	XHWRWCSCBDLOLM-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3

IUPAC name: 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one

Also known as: Nolatrexed, SID50125758, NOLATREXED, Nolatrexed Dihydrochloride

Parent form; salt/anhydrous children: CHEMBL1983788, CHEMBL2356692

Patent coverage: 2,409 distinct patent families (9,952 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,599 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Thymidylate synthase.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TYMS	7.82	Ki	15	nM	CHEMBL_ACT_655948
TYMS	7.8	Ki	16	nM	CHEMBL_ACT_655949

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00012324	PHASE3	COMPLETED	Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).